A reported clinical trial suggests that a high-dose radiotherapy approach could wipe out prostate tumours in many patients using a single session. The coverage focuses on the reduction in treatment appointments, describing the change as significant because it would allow clinicians to treat patients more efficiently and potentially reduce hospital waiting lists. The reports also note that fewer sessions would lessen the burden on patients, who otherwise would need to make multiple trips to receive radiotherapy. Both sources present the trial as an advancement in prostate cancer care, highlighting outcomes indicating that most men in the study reach tumour eradication after just one high-dose treatment. The articles cite charitable support for the model, framing the shorter course as impactful for patient experience and service capacity. The reporting emphasizes convenience and potential system-wide benefits linked to fewer visits, while the core claim is that the one-session treatment leads to tumour disappearance in the majority of participants in the trial.